Allergan in €1.7 Billion Offering
December 7, 2018
Cleary Gottlieb represented Allergan plc in a public offering of €500 million 1.5% notes due 2023, €500 million 2.625% notes due 2028, and €700 million floating rate notes due 2020.
The notes were issued by Allergan Funding SCS, a wholly owned subsidiary of Allergan, and conducted pursuant to Allergan Funding SCS’ automatic shelf registration statement. Allergan intends to use the proceeds from the offering for general corporate purposes, which may include funding the purchase and retirement of debt in open market transactions through full or partial redemptions or otherwise.
Barclays, Goldman Sachs, J.P. Morgan, and Morgan Stanley acted as the joint bookrunning managers of the offering, which closed on November 15, 2018.
Allergan is a global pharmaceutical company and is focused on developing, manufacturing, and commercializing branded pharmaceutical, device, biologic, surgical, and regenerative medicine products for patients around the world.